



2015-08-17

PRESS RELEASE

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow

New York, August 17, 2015 -- Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission to include final full-year financials in connection with its proposed public offering of American Depositary Shares representing its Ordinary Shares and contemporaneous listing of the American Depositary Shares on the US Nasdaq Capital Market.

Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, which is expected to close in August 2015, subject to customary closing conditions. The number of American Depositary Shares, representing Ordinary Shares, to be offered, and the price of the American Depositary Shares to be sold in the offering have not yet been determined. An Investor Roadshow will be conducted in the US during August 2015.

The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: info@oasmia.com. In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.oasmia.com.

For more information, please contact:

Julian Aleksov, Executive Chairman,
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com

Anders Lundin, Chief Financial Officer
Mobile: +46 70 20 96 300
E-mail: anders.lundin@oasmia.com

Eric Fischgrund
FischTank Marketing and PR
E-mail: eric@fischtankpr.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Oasmia Pharmaceutical AB Forward Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information that is currently available, as well as assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, industry and market conditions, and changes of interest rate and currency exchange rate, in general, and completion and discontinuation of clinical trials, obtaining regulatory approvals, claims and concerns about product safety and efficacy, technological advances, domestic and foreign healthcare reforms, and changes of laws and regulations, in particular, with respect to each of Paclical and Paccal Vet. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This announcement contains information on pharmaceuticals (including pharmaceuticals under development) but is not intended to, and does not, make any representations, warranties or claims regarding the efficacy or effectiveness of these pharmaceuticals or provide medical advice of any kind.

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08.40, CET on August 17, 2014."